Faron Pharmaceuticals Oy (FARN)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

210.00p

Buy

220.00p

arrow-up0.00p (+0.00%)

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medicalconditions. The company currently has a pipeline focusing on acute organ traumas,vascular damage and cancer immunotherapy.
Prices updated at 19 May 2025, 12:24 BST
| Prices minimum 15 mins delay
|
Prices in GBX

Profit margins

No data available

Valuation

No data available

Profit margins data table

YearGross margin (%)Operating margin (%)Net margin (%)EBITDA margin (%)EBITDA
2024-----22m
2023-----28m
2022-----27m
2021-----21m
2020-----17m
2019-----13m
2018--103,426.32-105,715.79-104,542.11-20m
2017-----21m
2016--1,019.22-1,064.92-1,046.32-10m

Valuation data table

YearPrice / SalesPrice earningsPrice / Cash flow
2025---
2024---
2023---
2022---
2021---
2020---
2019---
2018915.92--
2017316.84--
201665.61--
201584.69--
Price/Forward earnings (YTD)
-3.22

Returns

Created with Highcharts 7.2.2Return on assets (%)Return on equity (%)Return on invested capital (%)20202021202220232024-5k-4k-3k-2k-1k0

Debt profile

Created with Highcharts 7.2.2Financial leverage20202021202220232024012345

Returns data table

YearReturn on assets (%)Return on equity (%)Return on invested capital (%)
2024-227.96--
2023-287.97--
2022-234.98--
2021-196.71-3,961.50-536.18
2020-182.43--
2019-145.65-1,340.27-378.98
2018-175.51-785.84-413.43
2017-137.50-320.47-236.68
2016-66.33-103.56-86.32

Debt profile data table

YearFinancial leverage
2024-
2023-
2022-
20214.52
2020-
20196.34
201821.69
20173.14
20161.87
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.